Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Report this comment to a moderator

Please fill in the form below if you think a comment is unsuitable. Your comments will be sent to our moderator for review.
By submitting your information you agree to our Privacy and Cookie Policy.

Report comment to moderator

Required fields.


NICE rejects bowel cancer drug


> Perhaps if Roche slashed the vast profits made from this drug many would benefit. The unfortunate patients with bowel cancer would benefit. However, since new drugs, such as Avastin, cost on average £ 0.3 - 0.5 billion and take around 10 years to develop, Roche need to charge high prices to recoup their huge investment. Without this we would repidly see the end of the development of any new drugs.

Posted date

27 August, 2010

Posted time

11:18 am